Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

0.9085
-0.0218-2.34%
Post-market: 0.91700.0085+0.94%19:58 EST
Volume:190.19K
Turnover:170.84K
Market Cap:23.77M
PE:-0.32
High:0.9400
Open:0.9400
Low:0.8600
Close:0.9303
52wk High:5.10
52wk Low:0.7970
Shares:26.16M
Float Shares:9.58M
Volume Ratio:0.69
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8700
EPS(LYR):-12.0350
ROE:-394.62%
ROA:-67.77%
PB:2.93
PE(LYR):-0.08

Loading ...

Senti Biosciences to Present Gene Circuit Platform at Healthcare Conference Taipei

Reuters
·
Feb 03

Press Release: Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

Dow Jones
·
Jan 14

Senti Biosciences CEO to Join Cell and Gene Therapy Panel at Biotech Showcase

Reuters
·
Jan 09

Senti Biosciences Grants Stock Options to New Employee

Reuters
·
Dec 19, 2025

Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating

MT Newswires Live
·
Dec 10, 2025

Senti Biosciences Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 10, 2025

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news
·
Dec 10, 2025

Senti Biosciences (SNTI.US) Surges Over 7% at Open on Positive Phase 1 SENTI-202 Trial Data

Stock News
·
Dec 09, 2025

Senti Biosciences Reports Promising Clinical Results for SENTI-202 in AML Trial

Reuters
·
Dec 09, 2025

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Senti-202 in the Treatment of Adults With Relapsed or Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
Dec 09, 2025

Senti Biosciences Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 21, 2025

Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment

TIPRANKS
·
Nov 21, 2025

Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 20, 2025

Cell therapy developer Senti Biosciences' Q3 net loss narrows

Reuters
·
Nov 14, 2025

BRIEF-Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 14, 2025

Senti Biosciences Q3 EPS USD -0.69

THOMSON REUTERS
·
Nov 14, 2025

Press Release: Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Dow Jones
·
Nov 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Reuters
·
Oct 15, 2025

BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes

Reuters
·
Oct 14, 2025

Senti Biosciences Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 14, 2025